Register
Login:
Share:
Email Facebook Twitter

EXCLUSIVE: Aura Energy #Aura to IPO Swedish Vanadium prospect Watch Here

EXCLUSIVE: Aura Energy #Aura to IPO Swedish Vanadium prospect


Plethora Solutions Holdings PLC Share Chat (PLE)


PLE Share Chat
PLE Share Chat
PLE Level 2 Console
PLE Level 2 Console
PLE Live Share Price
PLE Live Share Price
Buy PLE Shares
Buy PLE Shares
Add PLE to Watchlist
Add PLE to Watchlist
Add PLE to Alert
Add PLE to Alert
Close Info Alerts is a Premium Feature
Login or start your FREE trial today.
Add PLE to myTerminal
Add PLE to myTerminal

There is currently no data for Plethora Solutions Holdings PLC.


Share Discussion for Plethora Solutions Holdings PLC


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


NIGELFOREST
Posts: 192
Off Topic
Opinion:No Opinion
Price:0.00
View Thread (2)
re: comedy gold
Today 13:51
Pomander - he couldn't name anyone, he's full of hot air. Don't believe a word he says, as most people on here are beginning to realise.
 
pomander
Posts: 5,424
Off Topic
Opinion:No Opinion
Price:0.00
RE: Re :comedy gold
Today 10:12
Alq- care to name the rumoured bidder ?
Rhines
Posts: 259
Off Topic
Opinion:No Opinion
Price:0.00
RE: ReL comedy gold
Fri 23:32
Exactly, sounds like a 'money fountain' to me. The only thing comedy gold is his desperate behaviour.
NIGELFOREST
Posts: 192
Off Topic
Opinion:No Opinion
Price:0.00
View Thread (3)
ReL comedy gold
Fri 17:02
and the question is this...………..WTF is he still posting on here then? If it's all true, which I don't believe for a minute!
pomander
Posts: 5,424
Off Topic
Opinion:No Opinion
Price:0.00
RE: Re :comedy gold
Fri 14:15
You forgot Amarin - another JM disaster.

As for buying in at 2p and selling out at 18 p, that cannot be viewed as a disaster. As yo well know pharma investing is often about capturing the hype and getting out before reality dawns.
Alquemie
Posts: 940
Off Topic
Opinion:No Opinion
Price:0.00
View Thread (2)
RE: Re :comedy gold
Fri 13:19
Pomander, I've never relied on Mr Mellon for my mess of potage, but as a self-proclaimed biotech investment guru, he hasn't half made some risible predictions and recommendations (PLE, DBC, which should really be renamed, "WTF", Arrowhead, the gone and forgotten Burnbrae investments. I share your ambivalence regarding SUMM).

The jolly wheeze that is Juvenesence also gives off a strong whiff of oversell, but I'm sure that they'll be no shortage of Mellonanists queuing up to support an IPO.

JG is an easy target, but he was handed a hard row to hoe, made harder by the expectation created by unfeasible revenue projections. I think it reasonable to suppose that his background has not equipped him to deal with issues which would tax any pharma old hand (scant intellectual property/commercial protection, undefined regulatory paths, an inadequate clinical dossier, manufacturing issues with cost overruns, positioning of an Rx product in what is essentially and OTC market).

True, plenty of people around capable of advising on any and all of these issues, but unless you fully grasp how it all fits together, damned difficult to know what you don't know. What is inexcusable is, whether through naivety or cupidity, his history of miscommunication, although I guess total silence is technically not "miscommunication".

This has been covered before, but the canister size has made no difference to the NDA submission timeline. The rate-limiting step has always been securing FDA agreement over definition, capture and measurement of subjective endpoints. Everything now rides on successful clinical validation in the (still to be registered) two part Phase III study, although there are several other critical boxes to be ticked.

Bunion: for the record (and it's in my posting history), having bought in large at sub-2p (on the back of a very strong acquisition rumour and with a large, unanticipated, bonus burning a hole in my pocket) and sold at around 18p on EMA approval, PLE, my one and only AIM investment, paid handsomely, thank you.

My only regret, one almost certainly shared by many, is that I did not dump the lot back in November 2013. The remainder was dribbled out on spikes, last tranche going at around 5p on the back of the RP acquisition rise.
bunion
Posts: 313
Observation
Opinion:Buy
Price:0.00
View Thread (2)
RE: Re :comedy gold
Fri 11:04
We must remember that Alq admitted a couple of years ago that having bought Plethora and lost money on his investment, he has held a grudge against the company ever since.
As regards Regent, I think we all have been disappointed with the managements past performance together with promises of early "money fountains"..........but with a professional pharma company in Recordati now distributing Fortacin across Europe hopefully we should see some long awaited returns for our patience..........I have been considering topping up again at these prices........
pomander
Posts: 5,424
Off Topic
Opinion:No Opinion
Price:0.00
RE: Re :comedy gold
Fri 10:47
Pikey - my point was that it seems somewhat churlish of Alq to ridicule one of the UK's most successful entrepreneurs on a matter unrelated to RP, unless of course he has his own axe to grind with respect JM. Perhaps he was a former consultant to Ple removed by JM ? His deep knowledge of events going back several years would seem to support this.

Whilst I understand your frustration with JG I am not sure that all the failings can be laid at his doorstep. The specialist pharma experience lies with Dr Mike and no doubt he will have been assisted by external pharma consultants.

The decision to produce a 6 dose can at the request of Recordati was clearly a catastrophic one and why the FDA submission was not simply advanced with the original 20 dose canister has never really been explained. Had it done so, the changes in FDA regulation may well have been avoided but they are now of the control of RP.

My disappointment with JG was his failure to explain clearly why the €5m milestone from Recordati had been delayed. He also provided Bignose which much dud information, but was that deliberate or just his best understanding of the situation at the time.?

I have always believed that a pharma investment company should be headed up by an experienced pharma specialist, a background in mining makes little sense unless the only objective here is to flog RP.
pikeypete
Posts: 652
Off Topic
Opinion:No Opinion
Price:0.00
View Thread (4)
Re :comedy gold
Fri 04:20
well pom , I respect your views, plus still believe we have a great product that should do well despite mellons and Gibson ,,, if mellons has had to cut a lot of dead wood , WHY is Gibson still here , no extra licence deals ,, misleads all the time to share holders ,, does not communicate to share holders , in fact does very little but take a huge salary,, perhaps jim believes he is doing a great job ? well I don't , I suggest any one thinking of investing in a mellons company think again , this company is run very , very . badly , and that's being polite, Gibson on face value is a waste of space , I would be happy to say sorry , if proved wrong , just want my money back after five crap years ...
Alquemie
Posts: 940
Off Topic
Opinion:No Opinion
Price:0.00
RE: Comedy gold
Thu 17:42
Oh, I dunno- I thought Ken Dodd's tax arrears alone were in the same ballpark?




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.